Clinical Trials Logo

Filter by:
NCT ID: NCT06139575 Recruiting - Prostate Cancer Clinical Trials

Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer

Start date: December 22, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of Lutetium Lu 177 JH020002 Injection in adult patients with advanced prostate cancer.

NCT ID: NCT06139536 Recruiting - Clinical trials for Advanced Solid Tumor

Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients

Start date: March 6, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BAT4706 Injection Combined With BAT1308 Injection in Patients With Advanced Solid Tumors.

NCT ID: NCT06139484 Recruiting - Clinical trials for Transcranial Magnetic Stimulation

Stanford Neuromodulation Therapy (SNT) for Non-suicidal Self-injury (NSSI)

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

To investigate the treatment effect of Stanford Neuromodulation Therapy (SNT) on patients with Non-suicidal Self-injury (NSSI) and the underlying neural mechanism.

NCT ID: NCT06139419 Recruiting - Clinical trials for Non-small Cell Lung Cancer

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Start date: July 25, 2023
Phase: Phase 2
Study type: Interventional

This prospective phase II randomized study is to determine the impact of thymosin alpha-1 on the concurrent chemoradiotherpay followed by immunotherapy consolidation in patients with locally advanced NSCLC by assessing the survival outcomes, treatment responses and toxicities.

NCT ID: NCT06139081 Recruiting - Hypoxemia Clinical Trials

Oxygen Delivery Methods of Nasal Catheter on the Incidence of Hypoxemia in Patients With Painless Gastroscopy

Start date: September 22, 2023
Phase: N/A
Study type: Interventional

In this study, patients undergoing painless gastroscopy were selected to change the nasal catheter oxygen delivery mode to oral oxygen delivery after endoscope implantation, in order to explore the effect of this oxygen delivery mode on the incidence of hypoxemia during general anesthesia gastroscopy.

NCT ID: NCT06139042 Recruiting - Pancreatic Cancer Clinical Trials

Early-stage Detection of LIver, Biliary tRAct and pancReatic Cancers

Start date: November 1, 2023
Phase:
Study type: Observational

LIBRARY is a prospective, multi-center, observational study aimed at detecting early liver, biliary tract, and pancreatic cancers by combining assays of cell-free DNA (cfDNA) methylation, serum protein, and microRNA.

NCT ID: NCT06138496 Recruiting - Clinical trials for Clear Cell Renal Cell Carcinoma

Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Start date: September 1, 2023
Phase: Phase 2
Study type: Interventional

Through the neoadjuvant treatment with a combination of Cardonilli and Lenvatinib, it enabled the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who had indications for nephron-sparing surgery but faced considerable difficulty in preserving the kidney (T1b with an endophytic component ≥75% or T2)

NCT ID: NCT06138353 Recruiting - Clinical trials for Subarachnoid Hemorrhage, Aneurysmal

Shuxuening Injection for the Prevention of CVS in Patients With aSAH(SXN-CVS)

SXN-CVS
Start date: January 24, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Aneurysmal subarachnoid hemorrhage (SAH) is a frequent worldwide cause for stroke with a mortality of around 30%. Worldwide, almost 500 000 patients have aneurysmal SAH annually.An incidence of 2-16 cases of spontaneous SAH per 100 000 person-years was reported in a recent meta-analysis . Surgical treatment of aneurysms is essential in the acute phase of aSAH patients, either by surgical clipping or by endovascular embolization. Although there are many factors that influence the prognosis of patients with aSAH, cerebral vasospasm (CVS) and delayed cerebral ischemia (DCI) are the main factors contributing to the high mortality rate (30-40% within 30 days) and poor long-term functional prognosis of patients after aSAH. Cerebral vasospasm (CVS) is defined as focal or diffuse temporary narrowing of vessel diameter due to contraction of smooth muscle in the arterial wall, which can be detected by digital subtraction angiography (DSA), transcranial ultrasound Doppler (TCD), magnetic resonance (MR), and CT angiography (CTA) or visualised during intraoperative.The prevalence of CVS after aSAH is 67% , with symptomatic patients (symptomatic vasospasm) in 30-40% of them and leading to ischaemic events in 10-45% of patients. It usually begins 3-4 days after bleeding, peaks at 7-10 days and finally resolves at around 14-21 days. There is no effective treatment to prevent cerebral vasospasm events.Shuxuening Injection is a sterilized aqueous solution made by extraction of Ginkgo biloba. The study aims to clarify the clinical study of the efficacy and safety of Shuxuening Injection (10ml/branch) for the prophylactic of cerebral vasospasm (CVS) after aneurysmal subarachnoid hemorrhage.

NCT ID: NCT06138340 Recruiting - Clinical trials for Postoperative Delirium

The Effects of Anesthetics on Brain Network Connectivity in Patients With Supratentorial Glioma

Start date: August 31, 2023
Phase:
Study type: Observational

Perioperative anesthesia can affect postoperative cognitive function. In our previous study, intraoperative dexmedetomidine (Dex) infusion reduced the incidence of delirium within the first 5 days after brain tumor. However, the mechanism is still unclear. With the development of neuroimaging, multimodal neuroimaging technology provide a new method to explore the underlying mechanism. Therefore, the purpose of this study is to analyze the alterations of brain network under sedation and anesthesia by different anesthetics in patients with supratentorial glioma and their association with cognition.

NCT ID: NCT06138210 Recruiting - Clinical trials for Acute Ischemic Stroke

The Effect of GD-iExo-003 in Acute Ischemic Stroke

ExoCURE
Start date: May 27, 2024
Phase: Phase 1
Study type: Interventional

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-escalation trial. The objective of this study is evaluating safety and preliminary efficacy of intravenous exosomes derived from human induced pluripotent stem cell (GD-iExo-003) in acute ischemic stroke.